top of page
TUXEDO-3
MULTICENTER, SINGLE-ARM, 3 COHORT, PHASE II TRIAL OF HER3-DXD IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM METASTATIC BREAST CANCER AND NON-SMALL CELL LUNG CANCER, AND IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM ADVANCED SOLID TUMORS.
CLINICAL TRIAL DETAILS
THE PRIMARY OBJECTIVES ARE TO ASSESS THE EFFICACY OF PATRITUMAB DERUXTECAN BY EVALUATING THE INTRACRANIAL OBJECTIVE RESPONSE RATE IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM METASTATIC BREAST CANCER AND ADVANCED NON-SMALL CELL LUNG CANCER AND TO ANALYZE THE OVERALL SURVIVAL RATES AT 3 MONTHS IN PATIENTS WITH ADVANCED SOLID TUMORS WITH UNTREATED LEPTOMENINGEAL DISEASE. THE STUDY WILL ALSO ASSESS THE ORR, DISEASE CONTROL RATE, TIME TO RESPONSE, DURATION OF RESPONSE, BEST PERCENTAGE CHANGE IN TUMOR BURDEN, OVERALL SURVIVAL, SAFETY, QUALITY OF LIFE, AND NEUROCOGNITIVE AND NEUROLOGICAL FUNCTION.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
Breast cancer and NSCLC with brain metastases; Leptomeningeal disease from advanced solid tumors
0
60
II
Spain, Austria
Follow up
TRIAL OVERVIEW
PRESS RELEASE
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
-
TRIAL SITES
Hospital Arnau de Vilanova de Valencia (Spain)
Hospital Universitari Dexeus (Spain)
Hospital Quirónsalud Sagrado Corazón (Spain)
Hospital Ruber Internacional (Spain)
Hospital Universitari Vall D’Hebron (Spain)
Hospital Universitario Virgen del Rocío (Spain)
Medical University of Vienna (Austria)
Medizinische Universität Innsbruck (Austria)
Salzburg Cancer Research Institute (Austria)
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page